Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBODY 2 epratuzumab in moderate to severe systemic lupus erythematosus
NL-OMON35730Phase 3Not yet recruiting
- Sponsor
- UCB
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Epratuzumab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Primary efficacy responder rate at Week 48. Planned start Jul 2011; status: not yet recruiting.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON35730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35730.